- advertising -

Frank Clyburn appointed CEO and member of the Board of Directors of IFF

IFF announces the appointment of Frank Clyburn to succeed Andreas Fibig as CEO and member of the Board of Directors, effective February 14, 2022.

Frank Clyburn joins IFF from Merck, where he served as executive vice president and president of the Human Health Division. 

During his time at Merck, he was also responsible for building one of the world's largest oncology businesses, which is now transforming cancer care and is Merck's largest business. He was an integral part of Merck's $41 billion acquisition of Schering-Plough.

Prior to this role, Frank Clyburn served as Merck's chief commercial officer, responsible for commercial operations and P&L for the Human Health division. From 2013 to 2018, he served as the inaugural president of the company's global Oncology business. He led the creation of this fully integrated global business unit, the global launch of Merck's immuno-oncology drug, and oversaw the arrival and sustainability of Merck as a leader in oncology.

Frank Clyburn has a deep understanding of R&D, extensive experience in integration and mergers and acquisitions, and a unique ability to connect with customers and all stakeholders. He was responsible for the largest business creation at Merck and for what is now one of the world's leading oncology companies.

"Frank is the best leader to take IFF to a new level. His strong operational experience and hands-on, customer-centric approach will be key assets in accelerating the execution of IFF's strategic and operational priorities."said Dale Morrison, director of IFF. 

Ed Breen, director of IFF, adds: "Frank joins IFF at a time of significant value creation opportunities. We are confident in his ability to deliver profitable growth, create synergies, optimize merger integration to deliver strong shareholder value."

"It is an honor to join IFF as CEO, said Frank Clyburn. It is a highly iconic company in its industry as well as an industry leader, delivering an exceptional customer experience and long-term sustainable growth. IFF's mission and vision are closely aligned with global trends that have accelerated recently, such as nutrition, wellness and sustainability. I look forward to working with IFF's talent, unparalleled product offerings, and particularly impressive innovation platforms, and am excited to bring my expertise in operational excellence to continue building IFF's future."

"I am pleased to welcome Frank to the role of CEO, said Andreas Fibig. He joins IFF at a time when we are meeting our financial targets for the full year 2021, with strong demand continuing into the first quarter. I am confident that Frank will motivate and engage our teams around the world, and I wish him every success in this next chapter of IFF under his leadership."

IFF also announces its decision to separate the roles of Chairman and CEO. Dale Morrison, a long-time IFF director, will assume the role of non-executive chairman of the board, effective February 14, 2022. Ed Breen will remain on the board as an independent director; therefore, there will no longer be a lead independent director in the company. 

External resources

Sponsored content

site-industries-cosmetiques A woman in a green shirt is featured in the article on automotive drafts.

From in vitro medical diagnostics to expertise in cosmetic microbiology

bioMérieux's industrial unit (sales of €549 million in 2022) has been supplying microbiological control solutions to the food industry for over 30 years...
site-industries-cosmetiques A modernized machine in a factory quality control laboratory.

Modernize Your Quality Control Lab

Revolutionize your QC testing at a fraction of the cost, delivering quicker results, shortening supply chain, and accelerating product decisions.

Related articles

Our last issue

Listen to us!